A detailed history of Td Asset Management Inc transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Td Asset Management Inc holds 98,406 shares of AUTL stock, worth $222,397. This represents 0.0% of its overall portfolio holdings.

Number of Shares
98,406
Previous 207,048 52.47%
Holding current value
$222,397
Previous $720,000 50.42%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$3.38 - $4.69 $367,209 - $509,530
-108,642 Reduced 52.47%
98,406 $357,000
Q2 2024

Aug 02, 2024

SELL
$3.33 - $5.68 $450,742 - $768,833
-135,358 Reduced 39.53%
207,048 $720,000
Q1 2024

May 08, 2024

BUY
$5.39 - $7.29 $1.12 Million - $1.51 Million
207,106 Added 153.07%
342,406 $2.18 Million
Q4 2023

Feb 12, 2024

BUY
$2.13 - $6.63 $288,189 - $897,039
135,300 New
135,300 $871,000
Q1 2020

May 15, 2020

SELL
$4.2 - $13.0 $71,639 - $221,741
-17,057 Closed
0 $0
Q4 2019

Feb 11, 2020

SELL
$11.13 - $16.28 $34,191 - $50,012
-3,072 Reduced 15.26%
17,057 $225,000
Q3 2019

Nov 07, 2019

SELL
$9.79 - $16.72 $10,768 - $18,392
-1,100 Reduced 5.18%
20,129 $250,000
Q2 2019

Aug 01, 2019

BUY
$15.1 - $31.25 $161,268 - $333,750
10,680 Added 101.24%
21,229 $342,000
Q1 2019

May 08, 2019

BUY
$24.38 - $34.71 $9,752 - $13,884
400 Added 3.94%
10,549 $332,000
Q4 2018

Feb 01, 2019

BUY
$24.21 - $48.01 $4,842 - $9,602
200 Added 2.01%
10,149 $333,000
Q3 2018

Nov 01, 2018

BUY
$20.86 - $33.33 $6,258 - $9,999
300 Added 3.11%
9,949 $300,000
Q2 2018

Jul 31, 2018

BUY
$25.0 - $27.75 $241,225 - $267,759
9,649 New
9,649 $258,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $205M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.